Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group, 2-Arm Study to Show Superiority of the Oral Contraceptive SH T00658ID Over Ortho Tri-Cyclen Lo on Hormone Withdrawal-Associated Symptoms After 6 Cycles of Treatment.

Next Previous
Search
Trial Profile

A Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group, 2-Arm Study to Show Superiority of the Oral Contraceptive SH T00658ID Over Ortho Tri-Cyclen Lo on Hormone Withdrawal-Associated Symptoms After 6 Cycles of Treatment.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 25 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Estradiol valerate/dienogest (Primary) ; Ethinylestradiol/norgestimate
  • Indications Pregnancy
  • Focus Registrational; Therapeutic Use
  • Acronyms HARMONY-I
  • Sponsors Bayer

    • Most Recent Events

    • 05 May 2012 Results presented at the 60th Annual Meeting of the American College of Obstetricians and Gynecologists.
    • 20 May 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
    • 20 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top